Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in combination with boosted darunavir (DRV) in treatment experienced patients with HIV

被引：0
|
作者：
Hill, L. [1 ]
Momper, J. [2 ]
Abulhosn, K. [1 ]
Ballard, C. [1 ]
Young, M. [3 ]
机构：
[1] UC San Diego Owen Clin, San Diego, CA USA
[2] UC San Diego Skaggs Sch Pharm, San Diego, CA USA
[3] UC San Diego Hlth, Dept Med, San Diego, CA USA
来源：
HIV MEDICINE | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE2/56
引用
收藏
页码：81 / 81
页数：1
相关论文
共 50 条
  • [1] Hepatic safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
    Johnson, M.
    Taylor, S.
    Wei, X.
    Collins, S.
    Martin, H.
    HIV MEDICINE, 2019, 20 : 40 - 40
  • [2] The safety and efficacy of the use of Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) with boosted darunavir in clinical practice
    Tyler, Stephanie
    Collins, Nadine
    Barchi, Will
    Kulasegaram, Ranjababu
    HIV MEDICINE, 2022, 23 : 32 - 32
  • [3] DRUG INTERACTION POTENTIAL OF EMTRICITABINE (F; FTC)/TENOFOVIR (TFV) ALAFENAMIDE (TAF) (F/TAF) FIXED DOSE COMBINATION AND COBICISTAT (COBI)-BOOSTED DARUNAVIR (DRV).
    Custodio, J. M.
    Wang, H.
    Silva, A.
    Zhong, L.
    Zack, J. Z.
    Callebaut, C.
    McCallister, S.
    Kearney, B. P.
    Ramanathan, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S72 - S72
  • [4] Pharmacokinetics, safety and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed pregnant women with HIV
    Zhang, H.
    Martin, H.
    Lin, L.
    Davis, M.
    Huang, H.
    Xiao, D.
    Arora, P.
    Avihingsanon, A.
    Koenig, E.
    Palaparthy, R.
    Girish, S.
    Marathe, D.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2023, 26
  • [5] Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in women
    Kityo, C.
    Koenig, E.
    Avihingsanon, A.
    Supparatpinyo, K.
    DeJesus, E.
    Wang, H.
    Quirk, E.
    Martin, H.
    Elliott, C.
    Makadzange, T.
    HIV MEDICINE, 2018, 19 : S30 - S30
  • [6] Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults
    Orkin, C.
    Sax, P.
    Arribas, J.
    Gupta, S.
    Martorell, C.
    Stephens, J.
    Stellbrink, H-J
    DeJesus, E.
    Maggiolo, F.
    Huang, H.
    Acosta, R.
    Brainard, D.
    Collins, S.
    Martin, H.
    HIV MEDICINE, 2020, 21 : 18 - 18
  • [7] Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults
    Orkin, C.
    Sax, P. E.
    Arribas, J.
    Gupta, S.
    Martorell, C.
    Stephens, J. L.
    Stellbrink, H-J
    Dejesus, E.
    Maggiolo, F.
    Huang, H.
    Acosta, R.
    Brainard, D. M.
    Collins, S. E.
    Martin, H.
    HIV MEDICINE, 2019, 20 : 94 - 95
  • [8] Resistance profile analysis of treatment-experienced HIV-1-infected patients switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) plus darunavir (DRV)
    Margot, Nicolas
    Ram, Renee
    Das, Moupali
    Fordyce, Marshall
    McCallister, Scott
    Miller, Michael
    Callebaut, Christian
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [9] Strategic simplification: the efficacy and safety of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) plus darunavir (DRV) in treatment-experienced HIV-1 infected adults (NCT01968551)
    Huhn, G.
    Gallant, J.
    Wilkin, T.
    Callebaut, C.
    Fordyce, M.
    Das, M.
    Mccallister, S.
    Yau, S.
    HIV MEDICINE, 2016, 17 : 15 - 15
  • [10] Longer-term (96-week) efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in women
    Kityo, C.
    Hagins, D.
    Koenig, E.
    Avihingsanon, A.
    Chetchotisakd, P.
    Supparatpinyo, K.
    Gankina, N.
    Pokrovsky, V.
    Voronin, E.
    Stephens, J. L.
    DeJesus, E.
    Wang, H.
    Acosta, R.
    Brainard, D.
    Martin, H.
    Makadzange, T. A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 4 - 4
12345